Leerink Partners Cut Price Target on Alnylam Pharma (ALNY) to $120 Following 4Q Earnings

February 16, 2016 8:42 AM

Leerink Partners maintained an Outperform rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $120.00 (from $152.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found